1.70
+0.14(+8.97%)
Currency In USD
| Previous Close | 1.56 |
| Open | 1.55 |
| Day High | 1.7 |
| Day Low | 1.54 |
| 52-Week High | 42.2 |
| 52-Week Low | 1.15 |
| Volume | 856,826 |
| Average Volume | 1.57M |
| Market Cap | 82.12M |
| PE | -1.16 |
| EPS | -1.46 |
| Moving Average 50 Days | 1.94 |
| Moving Average 200 Days | 13.16 |
| Change | 0.14 |
If you invested $1000 in Cassava Sciences, Inc. (SAVA) 10 years ago, it would be worth $876.29 as of May 09, 2025 at a share price of $1.7. Whereas If you bought $1000 worth of Cassava Sciences, Inc. (SAVA) shares 5 years ago, it would be worth $1,231.88 as of May 09, 2025 at a share price of $1.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
GlobeNewswire Inc.
May 01, 2025 11:30 AM GMT
As SVP, Neuroscience, Dr. Bordey will lead Cassava’s ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01,
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
GlobeNewswire Inc.
Apr 21, 2025 8:30 PM GMT
AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nerv
Cassava Sciences Licenses Simufilam Method of Treatment Patent
GlobeNewswire Inc.
Feb 27, 2025 12:00 PM GMT
Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with simufilam of seizures related to rare neurodevelopmental diso